Compare Stocks: DBVT, IDYA, ALMS, and NAMS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$25.31 +3.7%	$26.19	$3.76 ▼ $31.35	$3.23B	-0.69	902,175 shs	1.22 million shs
DBVT DBV Technologies	$14.02 -0.1%	$15.21	$8.70 ▼ $26.18	$830.82M	-0.93	409,482 shs	128,541 shs
IDYA IDEAYA Biosciences	$36.30 -1.0%	$35.19	$23.23 ▼ $40.58	$3.22B	-0.1	723,754 shs	435,245 shs
NAMS NewAmsterdam Pharma	$26.98 +1.2%	$30.92	$23.05 ▼ $42.21	$3.19B	0.1	1.17 million shs	959,713 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+3.69%	-8.30%	-12.15%	+10.67%	+472.62%
DBVT DBV Technologies	-0.07%	+4.01%	-10.76%	-28.65%	+41.47%
IDYA IDEAYA Biosciences	-1.04%	-1.94%	-1.20%	+28.68%	+48.65%
NAMS NewAmsterdam Pharma	+1.16%	-3.51%	-15.63%	-23.87%	+4.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$25.31 +3.7%	$26.19	$3.76 ▼ $31.35	$3.23B	-0.69	902,175 shs	1.22 million shs
DBVT DBV Technologies	$14.02 -0.1%	$15.21	$8.70 ▼ $26.18	$830.82M	-0.93	409,482 shs	128,541 shs
IDYA IDEAYA Biosciences	$36.30 -1.0%	$35.19	$23.23 ▼ $40.58	$3.22B	-0.1	723,754 shs	435,245 shs
NAMS NewAmsterdam Pharma	$26.98 +1.2%	$30.92	$23.05 ▼ $42.21	$3.19B	0.1	1.17 million shs	959,713 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+3.69%	-8.30%	-12.15%	+10.67%	+472.62%
DBVT DBV Technologies	-0.07%	+4.01%	-10.76%	-28.65%	+41.47%
IDYA IDEAYA Biosciences	-1.04%	-1.94%	-1.20%	+28.68%	+48.65%
NAMS NewAmsterdam Pharma	+1.16%	-3.51%	-15.63%	-23.87%	+4.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.83	Moderate Buy	$40.30	59.23% Upside
DBVT DBV Technologies	2.71	Moderate Buy	$48.50	245.93% Upside
IDYA IDEAYA Biosciences	2.81	Moderate Buy	$50.13	38.09% Upside
NAMS NewAmsterdam Pharma	2.93	Moderate Buy	$49.33	82.85% Upside

Current Analyst Ratings Breakdown

Latest DBVT, IDYA, ALMS, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$25.00
8/6/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$51.00 ➝ $50.00
8/5/2026	IDYA IDEAYA Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $60.00
8/5/2026	IDYA IDEAYA Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$63.00 ➝ $59.00
8/3/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$25.00
7/20/2026	NAMS NewAmsterdam Pharma	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$58.00
7/20/2026	NAMS NewAmsterdam Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00
7/20/2026	NAMS NewAmsterdam Pharma	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NAMS NewAmsterdam Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$7.40M	436.17	N/A	N/A	$2.88 per share	8.79
DBVT DBV Technologies	$5.64M	147.21	N/A	N/A	$2.71 per share	5.17
IDYA IDEAYA Biosciences	$234.13M	13.62	N/A	N/A	$13.65 per share	2.66
NAMS NewAmsterdam Pharma	$22.50M	143.34	N/A	N/A	$5.28 per share	5.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-95.08%	-75.81%	N/A
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/3/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	N/A

Latest DBVT, IDYA, ALMS, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million
7/16/2026	Q2 2026	DBVT DBV Technologies	-$0.12	-$0.60	-$0.48	-$0.60	$0.90 million	$0.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	7.51	7.51
DBVT DBV Technologies	N/A	3.72	3.72
IDYA IDEAYA Biosciences	N/A	10.45	10.45
NAMS NewAmsterdam Pharma	N/A	9.03	9.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
DBVT DBV Technologies	71.74%
IDYA IDEAYA Biosciences	98.29%
NAMS NewAmsterdam Pharma	89.89%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
DBVT DBV Technologies	1.06%
IDYA IDEAYA Biosciences	4.70%
NAMS NewAmsterdam Pharma	12.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	127.49 million	84.53 million	N/A
DBVT DBV Technologies	80	59.22 million	58.59 million	Optionable
IDYA IDEAYA Biosciences	80	87.86 million	83.73 million	Optionable
NAMS NewAmsterdam Pharma	4	119.54 million	102.01 million	Optionable

DBVT, IDYA, ALMS, and NAMS Headlines

Recent News About These Companies

HC Wainwright Brokers Reduce Earnings Estimates for NAMS

August 10, 2026 | americanbankingnews.com

HC Wainwright Issues Pessimistic Outlook for NAMS Earnings

August 10, 2026 | marketbeat.com

Royal Bank Of Canada Cuts NewAmsterdam Pharma (NASDAQ:NAMS) Price Target to $50.00

August 9, 2026 | americanbankingnews.com

What is HC Wainwright's Forecast for NAMS FY2027 Earnings?

August 9, 2026 | americanbankingnews.com

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript

August 8, 2026 | seekingalpha.com

Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

August 8, 2026 | theglobeandmail.com

BMO Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)

August 7, 2026 | theglobeandmail.com

Equities Analysts Offer Predictions for NAMS FY2027 Earnings

August 7, 2026 | marketbeat.com

NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Cut to $50.00 by Analysts at Royal Bank Of Canada

August 6, 2026 | marketbeat.com

NewAmsterdam Pharma Company NV (NAMS) reports Q2 loss, lags revenue estimates

August 6, 2026 | msn.com

NewAmsterdam Pharma (NASDAQ:NAMS) Announces Quarterly Earnings Results

August 5, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day - Slideshow

August 5, 2026 | seekingalpha.com

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

August 5, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2026 | zacks.com

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

August 5, 2026 | globenewswire.com

RBC Capital Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)

August 2, 2026 | theglobeandmail.com

Janus Henderson Group PLC Sells 82,739 Shares of NewAmsterdam Pharma Company N.V. $NAMS

August 2, 2026 | marketbeat.com

NewAmsterdam Pharma Company N.V. $NAMS Stake Boosted by Stempoint Capital LP

July 30, 2026 | marketbeat.com

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

July 29, 2026 | markets.businessinsider.com

NewAmsterdam Pharma (NAMS) Projected to Announce Earnings on Wednesday

July 29, 2026 | marketbeat.com

Louise Frederika Kooij Sells 105,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, IDYA, ALMS, and NAMS Company Descriptions

Alumis NASDAQ:ALMS

$25.31 +0.90 (+3.69%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$25.05 -0.26 (-1.03%)

As of 08/14/2026 07:58 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

DBV Technologies NASDAQ:DBVT

$14.02 -0.01 (-0.07%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.04 +0.02 (+0.14%)

As of 08/14/2026 04:20 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

IDEAYA Biosciences NASDAQ:IDYA

$36.30 -0.38 (-1.04%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$36.83 +0.53 (+1.45%)

As of 08/14/2026 07:55 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

NewAmsterdam Pharma NASDAQ:NAMS

$26.98 +0.31 (+1.16%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$27.18 +0.20 (+0.72%)

As of 08/14/2026 07:34 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DBVT, IDYA, ALMS, and NAMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DBVT, IDYA, ALMS, and NAMS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DBVT, IDYA, ALMS, and NAMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, IDYA, ALMS, and NAMS Company Descriptions

Alumis NASDAQ:ALMS

DBV Technologies NASDAQ:DBVT

IDEAYA Biosciences NASDAQ:IDYA

NewAmsterdam Pharma NASDAQ:NAMS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DBVT, IDYA, ALMS, and NAMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DBVT, IDYA, ALMS, and NAMS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DBVT, IDYA, ALMS, and NAMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT, IDYA, ALMS, and NAMS Company Descriptions

Alumis NASDAQ:ALMS

DBV Technologies NASDAQ:DBVT

IDEAYA Biosciences NASDAQ:IDYA

NewAmsterdam Pharma NASDAQ:NAMS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools